| HUTCHMED Initiates Phase I Trials of HMPL-295 | Reach | 06.07.21 | 09:30:01 |
| Holding(s) in Company | RNS | 02.07.21 | 11:15:01 |
| Notice of Results | RNS | 02.07.21 | 09:30:01 |
| US FDA Accepts NDA Filing for Surufatinib | Reach | 01.07.21 | 11:00:01 |
| Holdings in Company | RNS | 30.06.21 | 10:02:01 |
| Total Voting Rights | RNS | 30.06.21 | 10:01:01 |
| Closing of Global Offering and Hong Kong Listing | RNS | 30.06.21 | 10:00:01 |
| Blocklisting Six Monthly Return | RNS | 29.06.21 | 07:00:04 |
| HUTCHMED Announces Pricing of Global Offering | RNS | 23.06.21 | 15:21:52 |
| Savolitinib approved in China for lung cancer | RNS | 22.06.21 | 18:22:05 |
| HUTCHMED Announces NMPA Approval of Surufatinib | RNS | 18.06.21 | 16:05:04 |
| HUTCHMED Launches Hong Kong IPO | RNS | 18.06.21 | 07:01:01 |
| Disclosure Update | RNS | 18.06.21 | 07:00:04 |
| Clinical Data to be Presented at ASCO21 | Reach | 20.05.21 | 07:00:11 |
| HUTCHMED to Host Company Update | Reach | 17.05.21 | 07:00:15 |
| HUTCHMED to Attend Upcoming Investor Conferences | Reach | 07.05.21 | 12:00:01 |
| Change of Company Name | RNS | 04.05.21 | 08:00:07 |
| Surufatinib FDA Rolling NDA Submission Completed | Reach | 04.05.21 | 07:00:14 |
| Second Price Monitoring Extn | RNS | 30.04.21 | 16:41:01 |
| Price Monitoring Extension | RNS | 30.04.21 | 16:35:30 |
